Rivaroxaban is an anti-Xa inhibitor and is available in 2.5mg, 10mg, 15mg and 20mg tablets.
Indications (1,2)
Rivaroxaban is indicated for:
Prophylaxis of venous thromboembolism following knee replacement surgery
Prophylaxis of venous thromboembolism following hip replacement surgery
Treatment of deep-vein thrombosis or pulmonary embolism
Prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism
Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation
Prophylaxis of atherothrombotic events in acute coronary syndrome (with aspirin alone or aspirin and clopidogrel)
Initiation
Baseline Activated Partial Prothrombin Time (aPTT), International Normalised Ratio(INR), haemoglobin, urea & electrolytes and liver function tests
Weigh patient and obtain height
Calculate baseline creatinine clearance (CrCl)
If switching from another anticoagulant to rivaroxaban:
Parenteral anticoagulants to rivaroxaban - Rivaroxaban should be started 0 to 2 hours before the time of the next scheduled administration of the parenteral medicinal product (e.g. LMWH) or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin)
Vitamin K antagonists to rivaroxaban VKA treatment should be stopped and rivaroxaban therapy should be initiated when the INR is <=3.0
Contra-indications (1,2)
Active bleeding; significant risk of major bleeding (e.g. recent gastro-intestinal ulcer, oesophageal varices, recent brain, spine, or ophthalmic surgery, recent intracranial haemorrhage, malignant neoplasms, vascular aneurysm); in acute coronary syndrome - previous stroke or transient ischaemic attack
Dosing advice for Rivaroxaban (3)
MHRA has received a small number of reports suggesting lack of efficacy (thromboembolic events) in patients taking 15 mg or 20 mg rivaroxaban on an empty stomach; remind patients to take 15 mg or 20 mg rivaroxaban tablets with food (4)
Reference:
Wirral University Teaching Hospital NHS Trust. Oral Anticoagulants (VKA and DOAC) Guidelines for prescribing, monitoring and management (Accessed 23/4/19)
NHS Specialist Pharmacy Service (October 2017). Suggestions for Drug Monitoring in Adults in Primary Care
West Cheshire Commissioning Group (April 24th 2019). Prescribing Guidance for Rivaroxaban.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page